
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934**

For the Month of March 2026

Commission File Number: 001-37710

HUTCHMED (CHINA) LIMITED
(Translation of registrant's name into English)

48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

HUTCHMED (CHINA) LIMITED

Form 6-K

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Announcement relating to vesting of awards under the long term incentive plan

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HUTCHMED (CHINA) LIMITED

By: /s/ Johnny Cheng
Name: Johnny Cheng
Title: Chief Financial Officer

Date: March 11, 2026



Vesting of awards under the Long Term Incentive Plan

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 11, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2025 annual results of HUTCHMED on March 5, 2026, the following awards granted under the Long Term Incentive Plan (“LTIP”) on June 5, 2023 to Dr Weiguo Su and Mr Johnny Cheng were vested on March 10, 2026:-

Award Holders	Number of ordinary shares
Person Discharging Managerial Responsibilities	
Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer)	524,079
Mr Johnny Cheng (Executive Director, Acting Chief Executive Officer and Chief Financial Officer)	202,238
Total	<u><u>726,317</u></u>

The notifications set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.

(a) Dr Weiguo Su

1	Details of the person discharging managerial responsibilities/person closely associated					
a)	Name	Dr Weiguo Su				
2	Reason for the notification					
a)	Position/status	Executive Director, Chief Executive Officer and Chief Scientific Officer				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	HUTCHMED (China) Limited				
b)	LEI	2138006X34YDQ6OBYE79				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument	Ordinary Shares of US\$0.10				
	Identification code	Ordinary Share with DI ISIN: KYG4672N1016				
b)	Nature of the transaction	Vesting of awards granted on June 5, 2023 under HUTCHMED's LTIP				
c)	Price(s) and volume(s)	<table border="1"><thead><tr><th>Price(s)</th><th>Volume(s)</th></tr></thead><tbody><tr><td>Nil</td><td>524,079 ordinary shares</td></tr></tbody></table>	Price(s)	Volume(s)	Nil	524,079 ordinary shares
Price(s)	Volume(s)					
Nil	524,079 ordinary shares					
d)	Aggregated information — Aggregated volume — Price	N/A				
e)	Date of the transaction	2026-03-10				
f)	Place of the transaction	Outside a trading venue				

(b) Mr Johnny Cheng

1	Details of the person discharging managerial responsibilities/person closely associated					
a)	Name	Mr Johnny Cheng				
2	Reason for the notification					
a)	Position/status	Executive Director, Acting Chief Executive Officer and Chief Financial Officer				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	HUTCHMED (China) Limited				
b)	LEI	2138006X34YDQ6OBYE79				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument	Ordinary Shares of US\$0.10				
	Identification code	Ordinary Share with DI ISIN: KYG4672N1016				
b)	Nature of the transaction	Vesting of awards granted on June 5, 2023 under HUTCHMED's LTIP				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Nil</td> <td>202,238 ordinary shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Nil	202,238 ordinary shares
Price(s)	Volume(s)					
Nil	202,238 ordinary shares					
d)	Aggregated information — Aggregated volume — Price	N/A				
e)	Date of the transaction	2026-03-10				
f)	Place of the transaction	Outside a trading venue				

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

CONTACTS

Investor Enquiries

+852 2121 8200 / ir@hutch-med.com

Media Enquiries

FTI Consulting –

+44 20 3727 1030 / HUTCHMED@fticonsulting.com

Ben Atwell / Tim Stamper

+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)

Brunswick – Zhou Yi

+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

Panmure Liberum

Nominated Advisor and Joint Broker

Atholl Tweedie / Emma Earl / Rupert Dearden

+44 20 7886 2500

Cavendish

Joint Broker

Geoff Nash / Nigel Birks

+44 20 7220 0500

Deutsche Numis

Joint Broker

Freddie Barnfield / Jeffrey Wong / Duncan Monteith

+44 20 7260 1000
